Protagonist Therapeutics, Inc annual report, FY2019

Protagonist Therapeutics, Inc. — 2019 Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2019; filed March 10, 2020. The filing is an annual report rather than a quarterly filing. Protagonist is a clinical-stage biopharmaceutical company with no approved products or product sales. Its pipeline includes PTG-300 for blood and iron disorders and PTG-200 and PN-943 for inflammatory bowel disease.

Financial Performance and Liquidity

Metric	2019	2018	Change
License and collaboration revenue	$0.2 million	$30.9 million	Down 99%
Research and development expense	$65.0 million	$59.5 million	Up 9%
General and administrative expense	$15.7 million	$13.7 million	Up 15%
Loss from operations	$80.5 million	$42.3 million	Loss increased 90%
Net loss	$77.2 million	$38.9 million	Loss increased 98%
Net loss per share	$2.98	$1.74	Loss per share increased
Cash used in operating activities	$41.5 million	$49.9 million	Use decreased
Cash, cash equivalents and marketable securities	$133.0 million	$128.9 million	Up $4.2 million

Operating and net margins were not economically meaningful because revenue was minimal and the company remains loss-making. The 2019 revenue decline primarily reflected a $9.4 million cumulative catch-up reduction related to the amended Janssen agreement and the timing of performance obligations.

2019 research and development spending included $30.3 million for PTG-300, $20.9 million for PN-943, $9.4 million for PTG-200 and $0.3 million for PTG-100.
Operating cash use was partially offset by $8.4 million of stock-based compensation and a $33.5 million increase in deferred revenue related to Janssen.
Investing cash outflow was $53.7 million, primarily reflecting purchases of marketable securities; capital expenditures were $1.0 million.
Financing cash inflow was $46.0 million, including $34.5 million from the ATM equity offering and $9.8 million of net proceeds from debt.
At December 31, 2019, total assets were $154.9 million, working capital was $109.9 million, accumulated deficit was $217.7 million and stockholders’ equity was $80.0 million.

Debt and Liquidity

In October 2019, Protagonist borrowed $10.0 million under a $50.0 million term loan facility; an additional $40.0 million was available subject to clinical milestones, timing and other conditions.
Long-term debt was $9.8 million net at year-end, bearing interest at 7.85% at December 31, 2019, with maturity in October 2023.
The facility is secured by substantially all assets other than intellectual property and certain excluded property, and includes minimum cash and other restrictive covenants. The company reported compliance with the covenants and no event of default.
Management stated that existing cash, marketable securities and debt availability were expected to fund operations for at least the next 12 months from the filing date, but substantial additional financing will be required for continued development and potential commercialization.

Material Changes and 2019 Developments

The Janssen collaboration was amended in May 2019, generating a $25.0 million cash payment and expanding research into second-generation IL-23 receptor antagonists. The company became eligible for an additional $5.0 million milestone, received in the first quarter of 2020.
PTG-300 entered Phase 2 studies in beta-thalassemia and polycythemia vera. Preliminary beta-thalassemia data showed dose-related reductions in serum iron and transferrin saturation, but higher or more frequent dosing and longer follow-up were needed to establish clinical efficacy and durability.
PN-943 completed Phase 1 testing in healthy volunteers. The company reported tolerability and pharmacodynamic target engagement consistent with greater potency than PTG-100.
PTG-200 advanced into a Janssen-led global Phase 2 Crohn’s disease study in the fourth quarter of 2019.
Development of PTG-100 was largely discontinued in 2018 and related wind-down costs and credits continued in 2019.
The company issued 2.85 million shares through its ATM facility for $34.5 million net proceeds, increasing shares outstanding from 23.2 million at year-end 2018 to 27.2 million at year-end 2019.
Adoption of ASC 842 added operating lease assets and liabilities to the balance sheet. The company reported a $6.0 million right-of-use asset and $7.2 million of operating lease liabilities at year-end.

Outlook, Risks and Unusual Items

Management expected PTG-300 beta-thalassemia efficacy results in 2020, intended to select an initial indication for potential pivotal development in 2020 and potentially begin a pivotal study in 2021.
A Phase 2 PTG-300 study in hereditary hemochromatosis began in January 2020, and an investigator-sponsored MDS study was planned for the first half of 2020.
PN-943 Phase 2 ulcerative colitis proof-of-concept enrollment was expected to begin in the second quarter of 2020, with topline data anticipated in the second half of 2021. PTG-200 Phase 2 Crohn’s disease results were expected in the first half of 2021.
The company has never generated product revenue, has no approved products and expects significant future losses. Clinical, regulatory, manufacturing, reimbursement and commercialization outcomes remain uncertain.
Janssen controls or shares important development activities for PTG-200 and second-generation compounds. Termination, delayed development or unfavorable collaboration decisions could materially reduce future payments and require Protagonist to fund additional development.
Key financial risks include dependence on additional equity or debt financing, potential dilution, debt covenants, and the possibility that cash resources may be consumed faster than expected.
The filing identified potential disruption from the emerging COVID-19 outbreak, including effects on clinical enrollment, trial sites, outsourced manufacturing and supplies from China and other affected regions.
Potential future obligations include up to $128.0 million of development, regulatory and sales milestones and low-single-digit royalties payable to Zealand Pharma if PTG-300 is successfully developed and commercialized without a partner.

Investor Verification Priorities

Verify the full Phase 2 beta-thalassemia data for PTG-300, including transfusion-burden reductions, hemoglobin response, dose durability and safety.
Track enrollment, endpoints and results for the PTG-300 PV and HH studies and the planned MDS study.
Confirm the timing and outcome of PTG-200 and PN-943 Phase 2 trials and Janssen’s continued development commitments.
Reconcile collaboration revenue recognition with cash received, the $41.5 million deferred revenue balance and the $112.9 million transaction price under the amended Janssen agreement.
Monitor cash burn, remaining debt availability, covenant compliance and the timing and terms of any future capital raises.
Assess dilution from the ATM program, outstanding warrants, stock options and other equity awards.
Evaluate the impact of COVID-19 or other supply-chain and clinical-trial disruptions on development timelines and liquidity.